Apps, biosensors and patient-centered technologies are now a common fixture in global households. With their popularity on the rise, so has their inclusion in clinical trials as usage in clinical trials is projected to surge up to 70 percent by 2025.
But patient-centered technologies are not created equal. What may work for one patient population may not be appropriate for others. Thorough testing and careful evaluation are essential prerequisites for identifying the best technology for your trial needs.
This moderated, interactive discussion with sensors and wearables experts will cover the topics of:
Keith has worked for Parexel for over fifteen years. His background includes product, corporate, and personnel management; sales and marketing; and information systems experience. These skills have been applied within the life sciences and health care industries through working with and for clinical trial sponsors, contract research organizations and technology partners. His areas of subject matter expertise include electronic clinical outcomes assessment, patient sensors and a broad range of eClinical technology used within clinical drug trials.
Nathan has worked for Parexel for seven years, and within the industry for 13 years. At Parexel, this has covered project and product management of technology solutions across connected devices, mobile applications and platform development including IRT and eCOA, amongst others. Prior to Parexel, Nathan oversaw the distribution and logistics of investigational medicinal products and medical devices for a large contract research organization. These skills have been applied within the life sciences and health care industries through working with and for clinical trial sponsors, CROs and technology partners. Nathan holds the position of Solution Architect & Program Director within Parexel's Scientific Data Organization, a team that brings innovation to clinical trials by utilizing wearable and connected devices, and real-world data.”
Jeremy Wyatt is the CEO of ActiGraph, a leading global provider of physical activity and sleep monitoring solutions for pharmaceutical and academic industries. With two decades of embedded hardware systems development and related cloud technology expertise, Jeremy has a uniquely well-rounded perspective on the challenges and opportunities of deploying wearable technologies to capture accurate and meaningful patient data. He is considered an industry thought leader and expert in the clinical biosensor space and is a frequent representative and contributor at clinical drug development commercial events, scientific consortiums, and FDA/EMA regulatory meetings. He has an undergraduate degree in electrical engineering from the University of Florida and an MBA from the University of West Florida. Jeremy is a member and contributor to the Digital Medicine (DiMe) Society and participates in various digital biomarker efforts with the Clinical Trial Transformation Initiative (CTTI).
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.